



DR. MIRA PAVLOVIC-GANASCIA

CURRICULUM VITAE

Personal details

Name: Mira Pavlovic-Ganascia
Education: MD
Endocrinology
Specialist in dermatology and sexually transmitted diseases

Professional experience

Current position:

- Member, NDA Advisory Board
- Founder, Medicines Development and Training Services

Previous positions:

- 2010-2015 - Deputy Director for Health Technology Assessment, European collaboration and international affairs, La Haute Autorité de Santé
- 2001-2010 – Head of Scientific Advice, French Medicines Agency
- 2000-2001 – Orphan drugs, French Medicines Agency
- 1998-2000 – Dermatology assessor, French Medicines Agency
- 1996-1998 – International clinical trials leader, Laboratoires Servier
- 1993-1996 – Clinical trials managing physician, Department of Dermatology, Hospital Ambroise Paré and Agence Nationale de Recherche sur le SIDA (ANRS)
- 1992-1994 – Assistant Professor Dermatology, Belgrade University

Area of Expertise

- Clinical development of medicinal products, medical devices, diagnostics and co-diagnostics for marketing authorization and reimbursement purposes in different fields of medicines
- Methodology of development: study designs, choice of endpoints and comparators to support regulatory and relative effectiveness claims
- Detailed knowledge of the European approval system including European Medicines Agency (EMA).
- Patient relevant endpoints and health-related quality of life assessment for regulatory and HTA purposes

Major projects

As Regulator:

- Vice Chair of CHMP Scientific Advice Working Party (SAWP) 2007-2010
- Alternate and Full member of the SAWP (1998-2007)
- French representative in the EMA Efficacy working party (2001-2010), Rapporteur and Co-rapporteur for several disease-specific and general guidelines on clinical development of medicinal products.
- EWP representative in the EMA Similar Biological Medicinal Products Working Party (BMWP) (2005-2010)

In Public Institution:

- Shaping Early European Dialogues (SEED): Charing and coordination of early dialogues (multi-HTA and parallel EMA-multi-HTA ED).
- EUnetHTA JA1 (2010 – 2012): coordination of methodology requirements for relative effectiveness assessment in Europe
- EUnetHTA JA2 (2012 – 2015): evidence generation for relative effectiveness assessment (regulatory and multi-HTA scientific advice including adaptive pathways, methodology guidelines)

Associations

Member of Société Française de Dermatologie and European Academy of Dermatovenerology

Publications

Publications and conference presentations on aspects of Health Technology and Relative effectiveness assessments as well as clinical development aspects.

The complete list can be provided upon request.